Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma. Issue 4 (2nd February 2022)

• Record Type: Journal Article
• Authors: Vinti, Luciana; Pagliara, Daria; Buffardi, Salvatore; Di Ruscio, Valentina; Stocchi, Francesca; Mariggiò, Elena; Parasole, Rosanna; De Matteo, Antonia; Petruzziello, Fara; Paganelli, Valeria; De Vito, Rita; Del Bufalo, Francesca; Strocchio, Luisa; Locatelli, Franco
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 4(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-02-02
• Subjects: brentuximab vedotin -- Hodgkin lymphoma -- immunotherapy -- pediatric -- refractory -- relapse; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29557
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90–120 mg/m 2 on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3‐year overall and progression‐free survivals are 78.1% and 67%, respectively.